BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.

doi:10.1016/S2213-2600(15)00544-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.

The Lancet. Respiratory medicine - 1 Feb 2016

Evans Jonathan D W, Girerd Barbara, Montani David, Wang Xiao-Jian, Galiè Nazzareno, Austin Eric D, Elliott Greg, Asano Koichiro, Grünig Ekkehard, Yan Yi, Jing Zhi-Cheng, Manes Alessandra, Palazzini Massimiliano, Wheeler Lisa A, Nakayama Ikue, Satoh Toru, Eichstaedt Christina, Hinderhofer Katrin, Wolf Matthias, Rosenzweig Erika B, Chung Wendy K, Soubrier Florent, Simonneau Gérald, Sitbon Olivier, Gräf Stefan, Kaptoge Stephen, Di Angelantonio Emanuele, Humbert Marc, Morrell Nicholas W

Abstract excerpt

BACKGROUND: Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH). However, the effect of BMPR2 mutations on clinical phenotype and outcomes remains uncertain. METHODS: We analysed individual participant data of 1550 patients with idiopathic, heritable, and anorexigen-associated PAH from eight cohorts that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Morphogenetic Protein Receptors, Type II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Familial Primary Pulmonary Hypertension

Share to Hypertension, Pulmonary

Share to Lung Transplantation

Share to Prognosis

Share to Proportional Hazards Models

Share to Survival Rate

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 26795434
DOI: 10.1016/S2213-2600(15)00544-5
PMCID: PMC4737700

Genes

BMPR2
PAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.PMID 26795434Read ↗

Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.Semantic proximity Read ↗

Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade.Semantic proximity Read ↗

Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.Semantic proximity Read ↗

Prevalence and clinical features of bone morphogenetic protein receptor type 2 mutation in Korean idiopathic pulmonary arterial hypertension patients: The PILGRIM explorative cohort.Semantic proximity Read ↗

Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.Semantic proximity Read ↗

Identification of a novel mutation in the BMPR2 gene in a pulmonary arterial hypertension patient using next-generation sequencing.Semantic proximity Read ↗

Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.Semantic proximity Read ↗

Recent advances in pulmonary arterial hypertensionSemantic proximity Read ↗

BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series)Semantic proximity Read ↗

Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.Semantic proximity Read ↗

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension.Semantic proximity Read ↗

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.